IMMUNE-MEDIATED PANCREATITIS

This adverse event was reported 381 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED PANCREATITIS:

# Drug Count
0 NIVOLUMAB 119
1 IPILIMUMAB 69
2 CARBOPLATIN 67
3 PACLITAXEL 52
4 PEMETREXED DISODIUM 20
5 BEVACIZUMAB 19
6 DURVALUMAB 18
7 OXALIPLATIN 12
8 PEMETREXED 12
9 TREMELIMUMAB 12
See all common drugs associated with IMMUNE-MEDIATED PANCREATITIS

IMMUNE-MEDIATED PANCREATITIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 CEMIPLIMAB-RWLC 6 0.0029
1 TREMELIMUMAB 12 0.0027
2 NIVOLUMAB AND RELATLIMAB-RMBW 1 0.0019
3 IPILIMUMAB 69 0.0016
4 NIVOLUMAB 119 0.0012
5 NALDEMEDINE 2 0.0012
6 DURVALUMAB 18 0.0008
7 HYALURONATE SODIUM 1 0.0007
8 TALIMOGENE LAHERPAREPVEC 1 0.0006
9 LEVOLEUCOVORIN 2 0.0005
See all drugs enriched for association with IMMUNE-MEDIATED PANCREATITIS